Apnimed

Q2 FY2026 EarningsApnimed (APMD) reported a massive EPS beat for Q2 2026, primarily driven by one-time strategic gains totaling $142.5M from the monetization of its Shionogi joint venture and a deposit liability reversal. While core R&D expenses declined 38% YoY due to the conclusion of Phase 3 trials, G&A expenses surged over 100% as the company ramps up commercial infrastructure for Oxnimbi™ (AD109). With a PDUFA date set for February 28, 2027, and a significantly strengthened cash position of over $420M (post-IPO/monetization), the focus shifts entirely to regulatory execution and market access prep for the first potential oral OSA treatment.